Purpose of review
The interest in quotidian hemodialysis has increased further after the HEMO study reported that high-dose thrice-weekly hemodialysis failed to improve clinical outcomes. This, in combination with a significant volume of newly published data, made a review of the topic of quotidian hemodialysis timely.

Recent findings
The published research has revealed further evidence of cardiovascular and quality-of-life improvements as well as financial benefits with quotidian hemodialysis. Accrued worldwide experience has confirmed the previously published benefits of quotidian hemodialysis. There has been a significant effort by industry to produce patient-friendly machines for home hemodialysis. Reports on the use of daily hemodialysis and hemodiafiltration in children have appeared. An international registry of patients on quotidian hemodialysis has been created. The need for modification of the funding mechanisms and the lack of prospective randomized controlled studies on quotidian hemodialysis led to the funding of such studies by the National Institutes of Health in collaboration with Centers for Medicare and Medicaid services to be completed by 2008. The proper funding for daily home hemodialysis was secured in the province of British Columbia, Canada, and is under consideration elsewhere.

Summary
There is increasing evidence confirming that quotidian hemodialysis improves clinical outcomes in a cost-efficient manner. Provided that the reimbursement issues are resolved these modalities may be utilized extensively at home as well as in the in-center facilities. The revitalization of home hemodialysis will compensate for the decline in utilization of continuous ambulatory peritoneal dialysis and the nursing shortage encountered in most countries.

Keywords
daily hemodialysis, home hemodialysis, nocturnal hemodialysis

Introduction
Since the HEMO study demonstrated that modest increases in dialysis dose did not reduce mortality in people receiving conventional thrice-weekly hemodialysis treatments [1], interest in intensive dialysis regimens including long intermittent hemodialysis, short quotidian hemodialysis and quotidian nocturnal hemodialysis has intensified [2]. The interest in convection techniques such as hemofiltration and hemodiafiltration has also increased [3,4]. In this review we will focus on recent clinical trial results that have studied the various forms of quotidian hemodialysis. Older references can be found in our previous review in this journal [5].

Technique advancements
The method of delivery of quotidian dialysis has been described previously [5]. Industry efforts have led to new hemodialysis machines that are simpler to operate. Some have unique features that are useful for short or long home hemodialysis [6–12], such as mobile flat screens, fewer alarms and easier setup. New capabilities include low dialysate flow, ultrapure dialysate, in-situ dialyzer reuse, hemoperfusion techniques, batch dialysate or sorbent cartridges. The need for remote monitoring for nocturnal hemodialysis is still debated, and not all units perform remote monitoring unless required by local regulatory bodies. The quality of monitoring is improving by extending it to include biological parameters [13,14]. Monitoring of a wide geographical area by a single center has been tried successfully.

Patient selection and training
Quotidian hemodialysis can be initiated by patients in order to improve quality of life or to have free time to work. Alternatively, patients start quotidian dialysis as a ‘rescue’ therapy. Ability and willingness to be trained as well as adequate housing are the only prerequisites for home techniques. Interestingly, a recent study suggests that only about half of patients would agree to come to the dialysis facility daily even if the benefits of quotidian hemodialysis were established [15]. In the current reimbursement structure the main indication for in-center quotidian hemodialysis is the presence of significant co-morbidities, hemodynamic instability or severe
malnutrition [16**]. Although the length of training for home hemodialysis for untrained patients is usually 5–8 weeks, attempts to increase training efficiency have been made.

**Blood access**

Although the use of native arteriovenous fistulae is encouraged for quotidian hemodialysis, synthetic grafts and central venous catheters can be used. Some centers use the buttonhole technique, where cannulation occurs repeatedly at the same site, often using non-cutting needles, which are guided by the tract into the fistula. The single-needle system may increase safety, patient comfort and improve access survival but can be utilized only for nocturnal hemodialysis, in which low blood flow rates are acceptable. Infectious and thrombotic access complications on quotidian hemodialysis are reported to be similar to, or less frequent than, conventional hemodialysis, but prospective studies are missing [17,18*,19*].

**Results**

The published outcomes of quotidian nocturnal hemodialysis will be discussed below.

**Kinetics and solute removal**

The solute-removal measure correlating best to clinical outcomes remains unclear. Potential candidates include the peak urea concentration, the equivalent kidney urea clearance (EKR) based on the average urea concentration (TAC), standard Kt/V (stdKt/V; where K is dialyzer clearance, t is dialysis time and V is urea volume of distribution) based on the average predialysis urea concentration [20**], and the normalized Kt/V based on the average concentration of a theoretical solute diffusing slowly across intercompartmental barriers and therefore better representing larger molecules [21*]. In order to explain the benefits of quotidian hemodialysis, these techniques have been extended to the comparison of larger molecule removal [22*]. stdKt/V based on the average predialysis urea, and therefore favoring the high-frequency regimens, has been the most popular method in the field [23*] and is advocated by some authorities [20**]. While conventional hemodialysis and peritoneal dialysis typically yield a stdKt/V of 2.0, the values for quotidian short hemodialysis and nocturnal hemodialysis are about 3 and 5 respectively [16**,23*,24*]. A weekly stdKt/V of 2 would be equivalent to a daily equilibrated Kt/V of 0.38 (six times a week). Convective techniques including hemofiltration and hemodiafiltration offer higher removal of larger molecules and therefore measures of urea kinetics likely underestimate dialysis adequacy [22*,25]. The use of about 15 l of replacement solution for daily hemofiltration 6 days a week in an average-sized patient provides a stdKt/V of about 2.0 per week, which is similar to conventional hemodialysis but lower than short daily hemodialysis of equal weekly duration [25]. Use of short daily hemofiltration has been associated with lower β2-microglobulin levels [3*]. Long hemodialysis is associated with increased middle-molecule removal and quotidian nocturnal hemodialysis offers a 4-fold increase in β2-microglobulin removal [5]. Advanced glycated end products and protein-bound molecules have been reported to decrease upon conversion from conventional to short daily hemodialysis [5]. While short daily hemodialysis reduces homocysteine levels, quotidian nocturnal hemodialysis appears to reduce these levels further [5,26*].

**Quality of life**

When quality of life was measured, quotidian dialysis was associated with a reduction in the number and severity of dialysis-related symptoms, as well as a reduction in time to recover from dialysis [27*]. Quality-of-life instruments such as the Kidney Disease Quality of Life (KDQOL), the Sickness Impact Profile (SIP), the Beck Depression Index, the RAND-36 and the SF-36 method have all reported higher global quality of life in quotidian-dialysis patients [16**,28**,29,30**,31,32*]. Utility scores assess a patient’s preference for health states and are graded on a scale between 0 (a quality of life equivalent to death) and 1 (the best quality of life imaginable) [33**]. Patients receiving conventional hemodialysis typically report utility scores of about 0.5, which represents a quality of life worse than in patients who suffer from blindness or paraplegia. Mean utility scores for patients receiving home quotidian hemodialysis were about 0.7, similar to historically reported values following kidney transplant [27*,33**].

**Calcium, phosphorus metabolism and bone disease**

Disorders of mineral metabolism contribute to cardiovascular disease in dialysis patients. Phosphate is removed by hemodialysis less efficiently than urea, due to its slow mobilization from the deep tissues. Consequently, an early decrease in serum phosphate during hemodialysis is followed by rebound prior to and after the end of dialysis [34]. High dialysis frequency increases phosphate removal by allowing daily equilibration of the serum levels and restoring the blood to dialysate gradient. However, the main determinant of phosphate removal is the duration of dialysis. A quantitative approach to phosphate removal has been recently described [35]. The effect of the two forms of quotidian dialysis on mineral metabolism is as follows.

**Short daily hemodialysis**

Unless dialysis time is longer than 2 h, short daily hemodialysis results in a minimal decrease in serum phosphate or phosphate binders, and no effect on parathyroid hormone [5]. Measurement of phosphate in dialysate suggests that phosphate removal increases on short daily
hemodialysis, but patients typically increase their protein intake, which minimizes the net effect on serum phosphate levels [36*].

**Quotidian nocturnal hemodialysis**

Quotidian nocturnal hemodialysis doubles phosphate removal when compared to conventional hemodialysis, allowing discontinuation of phosphate binders despite increased dietary phosphate intake. Typically phosphate must be added to the dialysate to avoid hypophosphatemia [5]. Normalization of serum phosphate typically results in normalization of the calcium phosphorus product [28**], and allows the safe increase in the dialysate calcium, which can result in higher serum calcium and lower parathyroid hormone levels without the use of vitamin D analogues. Tumoral calcinosis resolved in one patient after conversion to quotidian nocturnal hemodialysis [37].

Higher dialysate calcium losses and the discontinuation of phosphate binders can result in a negative calcium balance in patients performing quotidian nocturnal hemodialysis dictating high dialysate calcium [30**,38]. Dialysate calcium and phosphorus can be adjusted by the patients through the addition of powdered calcium chloride or sodium phosphate, the latter being added into either the acid or bicarbonate concentrate.

**Nutrition**

Most patients who convert to quotidian hemodialysis experience improved appetite. Reports on the short and long-term effects of quotidian nocturnal hemodialysis on serum albumin and weight are variable, with improvements seen in most [39*,40], but not all studies [16**]. High baseline co-morbidity appears to blunt the nutritional benefits of quotidian hemodialysis and this may explain the differences in serum albumin between patients on short and nocturnal quotidian hemodialysis reported in a recent study [26*]. The use of nocturnal hemodialysis or daily hemodiafiltration in children has led to improved nutritional status and accelerated growth [41,42].

**Cardiovascular disease**

Improvement in blood-pressure control without or with minimal use of medications has consistently been reported in both quotidian short and nocturnal hemodialysis [5]. Current understanding of the mechanism by which blood pressure is lowered by frequent dialysis suggest that quotidian short hemodialysis lowers blood pressure primarily via enhanced extracellular fluid volume control [43*,44*]. In contrast, quotidian nocturnal hemodialysis lowers blood pressure by a selective decrease in total peripheral resistance [45**]. Both forms of intensive hemodialysis have been suggested to regress left-ventricular hypertrophy not seen on intermittent long hemodialysis [43*,46]. Other cardiovascular effects unique to nocturnal hemodialysis include restoration of impaired left-ventricular systolic ejection fraction [47], correction of sleep apnea and restoration of cardiac autonomic balance during sleep [48*,49], improvement in flow-mediated dilation and endothelium-independent vasodilation [48*], restoration of impaired peripheral vascular flow [50] and an increase in serum high-density lipoprotein levels [51]. Further evidence for the vasodilatory effect of nocturnal hemodialysis has been an observed increase in blood pressure after transplantation. Conversely a decrease in blood pressure was observed after the transplantation of patients previously on conventional hemodialysis [52].

The difference in phosphate control between the two quotidian regimens may explain the dissimilar cardiovascular effects of the two regimens. The vascular responsiveness in patients before and after conversion to nocturnal hemodialysis was compared in patients with either high or normal baseline plasma phosphate levels. There was delay in the restoration of vascular responsiveness in the hyperphosphatemic cohort suggesting that phosphate control is related to the cardiovascular homeostasis [53**]. Coronary calcification, quantified using spiral computer tomography scan, was unchanged 1 year after conversion to nocturnal hemodialysis, suggesting a beneficial effect of the improved uremic control and normalization of serum phosphate [54**].

Patients on conventional hemodialysis have a 3–4-fold decrease in endothelial progenitor cell number and function, which are new cardiovascular prognostic indicators in the non-end-stage renal disease (ESRD) population, as compared to matched control [55*]. In contrast, patients on nocturnal hemodialysis have normal endothelial progenitor cell number and function, suggesting that improved uremic control may restore the balance between cardiovascular injury and repair [56**].

**Erythropoietin dose and anemia control**

There have been conflicting reports of the impact of quotidian hemodialysis on anemia management. Most groups described an increase in hemoglobin concentration and a fall in erythropoietin requirements of as much as 45% [16**]. However, negative results have also been reported [29,57]. Some of the negative results were ascribed to insufficient iron supplementation. Similarly, despite the lack of improvement in erythropoiesis in the early reports on nocturnal hemodialysis [58], a significant increase in hemoglobin levels and a decrease in erythropoietin requirements were reported recently [59]. Red-cell survival did not improve on quotidian hemodialysis [60]. Further prospective studies are needed to delineate the mechanisms and clinical impact of intensive hemodialysis on anemia control and erythropoietin responsiveness.
Sleep disorders such as sleep apnea, periodic limb movements and daytime sleepiness are highly prevalent in ESRD. Quotidian nocturnal hemodialysis has been demonstrated to normalize the sleep pattern in patients with prior sleep apnea [49]. However, the prevalence of daytime sleepiness did not change after conversion to quotidian nocturnal hemodialysis, and nor did the frequency of periodic limb movements [61*]. There are no data on the effect of short daily hemodialysis on sleep disorders.

Patient survival: hospitalization
An 80% 5-year patient survival on short daily hemodialysis has been described [62]. Similar results of 81% survival over 5 years were reported on quotidian nocturnal hemodialysis [30**]. Improved survival was reported using quotidian hemodialysis in acute renal failure [63]. Multicenter data on mortality from the quotidian hemodialysis registry [30**,64], as well as randomized prospective studies [65], are needed. Retrospective as well as prospective data suggest decreased hospitalization rates of patients on quotidian hemodialysis but more data are needed [16**,66,67].

Daily hemofiltration
There is only limited use of quotidian hemodialfiltration in-center for both adults and children or hemofiltration at home using pre-prepared sterile replacement solutions [3*,4*,42]. Lower predialysis serum β2-microglobulin has been reported with quotidian hemodialfiltration [3*]. Early clinical results from the use of the short daily hemofiltration are encouraging [4*].

Modality choices
There are no adequate studies comparing the forms of intensive hemodialysis. The advantages of quotidian nocturnal hemodialysis must be weighed against the requirement for long and frequent treatments, the potential for deficiency syndromes, long exposure to dialysis membranes and safety concerns at night. It is the preferred modality for increased dialysis requirements as with large body size, or in pregnancy [68*].

A prospective non-randomized study of 11 short daily, 12 nocturnal hemodialysis and matched controls receiving conventional hemodialysis for 5–36 months was published recently [14*,57,69**,70*,71]. The study confirmed improvements in quality of life and blood-pressure control for both quotidian modalities [27*,44*] and better phosphate control with nocturnal hemodialysis [23*,72**].

The main advantage of long intermittent hemodialysis is the favorable financial profile, the known improved hemodynamic benefits and the increased middle-molecule removal [2]. Hemofiltration has the added advantage of better removal of middle molecules which may lead to better outcomes.

Health economics: the costs of dialysis
In-center hemodialysis is one of the most expensive medical undertakings to ever be approved for widespread use. It is unclear if any therapy that adds to the cost of dialysis would be acceptable [33**]. However, quotidian dialysis is not only cost-effective, but also potentially cost saving.

The cost of in-center hemodialysis is estimated to be between $50 000 and $100 000 per patient-year (2003 US dollars) [72**]. Savings from quotidian dialysis must offset the expected rise in costs associated with higher treatment frequencies and, in the case of home hemodialysis, capital costs for water treatment and dialysis machines. Material costs more than double with quotidian dialysis, typically by about $8000 per patient-year [33**,66,69**]. Capital costs are about six times higher for home quotidian methods, typically increasing costs by about $5000 per patient-year [33**,66,69**].

The savings from decreased hospitalization associated with quotidian hemodialysis have varied from $1000 to $5000 per patient-year. Reduced medication use (primarily erythropoietin, cardiovascular medications and phosphate binders) has led to savings of between $2500 and $7000 per patient-year [33**,66,69**]. These savings may be enough to compensate for the higher material costs. Staffing costs of home hemodialysis have been reported to be between $8000 and $24 000 less per patient-year [72**]. Most studies report a reduction in overhead and support costs of about $5000 per year [72**].

These savings make quotidian dialysis cost-effective, with home modalities typically saving over $10 000 per patient-year over conventional hemodialysis [33**,66,69**]. When combined with the expected improvements in quality of life, these savings make quotidian hemodialysis the economically dominant option, both reducing costs and improving outcomes.

Current utilization of quotidian hemodialysis and obstacles
More than 1000 patients perform quotidian hemodialysis, with reports published from North and South America, Europe and Australia [16**,24**,28**,29,39*,40,58,62,73]. The main obstacle to the utilization of quotidian hemodialysis is the unfavorable reimbursement structure. Patient willingness and ability to perform home hemodialysis is a second barrier, as eligibility decreases with advancing age and co-morbidity.

Clinical as well as costing data from randomized controlled studies are needed [65]. The National Institutes...
of Health (NIH) and the Centers for Medicare and Medicaid services (CMS) have funded such studies aiming to compare short and quotidian nocturnal with conventional hemodialysis. The results of these studies are expected in 2008. An international quotidian hemodialysis registry already in operation will be useful in collecting data from many centers and provide pilot data for further studies [64].

Conclusion

Existing studies consistently demonstrate that quotidian hemodialysis provides improvement in quality of life, biochemical and cardiovascular parameters, and likely anemia and nutrition. Provided that a solution to the reimbursement problem is found, quotidian dialysis is expected to become a prevalent choice in the treatment of ESRD. The role of hemofiltration may also grow. These methods will provide revitalization of home hemodialysis, bringing social and vocational rehabilitation to more patients, while also providing a solution to the nursing shortage prevalent in many countries. Further studies of all aspects of quotidian hemodialysis are necessary to increase our understanding of the methods and also provide the data necessary for their appropriate reimbursement.

References and recommended reading

Papers of particular interest, published within the annual period of review, have been highlighted as:

• of special interest
•• of outstanding interest

1 Elkoyan G, Beck GJ, Cheung AK, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002; 347: 2010–2019.
2 Pierratos A. New approaches to hemodialysis. Annu Rev Med 2004; 55:179–189.
3 Maduell F, Navarro V, Torregrosa E, et al. Change from three times a week on-line hemodiafiltration to short daily on-line hemodiafiltration. Kidney Int 2003; 64:305–313.
4 Zimmerman DL. Hemofiltration as a treatment for end-stage renal disease. • Hemodial Int 2004; 8:183–187.
5 Review of hemofiltration with an emphasis on short daily hemodiafiltration.
6 Pierratos A. Daily hemodialysis: an update. Curr Opin Nephrol Hypertens 2002; 11:165–171.
• Our previous review including the older references.
7 Ledebo I, Fredin R. The Gambro system for home daily dialysis. Semin Dial 2004; 17:162–163.
8 Kjellstrand CM, Blagg CR, Bower J, Twardowski ZJ. The AKSYS personal hemodialysis system. Semin Dial 2004; 17:151–153.
9 Kelly TD. Baxter Aurora dialysis system. Semin Dial 2004; 17:154–155.
10 Schlaeper C, Diaz-Buxo JA. The Fresenius Medical Care home hemodialysis system. Semin Dial 2004; 17:159–161.
11 Ash SR. The Aliment Dialysis System. Semin Dial 2004; 17:164–168.
12 Trewin E. Bellco Formula Domus Home Care System. Semin Dial 2004; 17:158–160.
13 Clark WR, Turk JE. The NxStage System One. Semin Dial 2004; 17:167–170.
14 Hoy C. Remote monitoring in nocturnal home hemodialysis 2003. Hemodial Int 2004; 8:144–150.
15 Detailed review of remote monitoring for nocturnal hemodialysis.
16 Review of remote monitoring for nocturnal hemodialysis.

Quotidian dialysis – update 2005 Pierratos et al. 123

14 Heidenheim AP, Leitch R, Kortas C, Lindsay RM. Patient monitoring in the London daily/nocturnal hemodialysis study. Am J Kidney Dis 2003; 42:61–65.
15 Experience with monitoring of patients on nocturnal hemodialysis.
16 Halpern SD, Berns JS, Israni AK. Willingness of patients to switch from conventional to daily hemodialysis: looking before we leap. Am J Med 2004; 116:606–612.
17 Ting GO, Kjellstrand C, Freitas T, et al. Long-term study of high-comorbidity •• ESRD patients converted from conventional to short daily hemodialysis. Am J Kidney Dis 2003; 42:1020–1035.
18 Using in-center short daily hemodialysis as a rescue therapy.
19 Lockridge RS Jr, Spencer MO, Craft VW, et al. 6 Years of experience with nightly home hemodialysis access. Hemodial Int 2004; 8:79.
20 Twardowski ZJ. Blood access in daily hemodialysis. Hemodial Int 2004; 8; 70–76.
21 Very useful review of the topic of vascular access.
22 Gotch FA. Definitions of dialysis dose suitable for comparison of daily •• hemodialysis and continuous ambulatory peritoneal dialysis to conventional thrice weekly daily dialysis therapy. Hemodial Int 2004; 8:172–182.
23 Treatment on the issue of the preferable measure of dialysis dose with special reference to daily hemodialysis.
24 Depner TA, Bhat A. Quantifying daily hemodialysis. Semin Dial 2004; 17: 79–84.
25 Evaluating the approach to quantitation of daily hemodialysis dose.
26 Leypolde JK, Jaber BL, Lysaght MJ, et al. Kinetics and dosage predictions for daily haemofiltration. Nephrol Dial Transplant 2003; 18:769–776.
27 Comparison of kinetics of daily hemofiltration to different hemodialysis schedules.
28 Suri R, Depner TA, Blake PG, et al. Adequacy of quotidian hemodialysis. Am J Kidney Dis 2003; 42:42–48.
29 The London, Ontario study: urea kinetics.
30 Williams AW, Chebrolu SB, Ing TS, et al. Early clinical, quality-of-life, and biochemical changes of “daily hemodialysis” (6 dialyses per week). Am J Kidney Dis 2004; 43:90–102.
31 Comparison of the short-term results from short daily hemodialysis with those from conventional hemodialysis.
32 Leypolde JK, Jaber BL, Zimmerman DL. Predicting treatment dose for novel therapies using urea standard kt/v. Semin Dial 2004; 17:142–145.
33 Spanner E, Suri R, Heidenheim AP, Lindsay RM. The impact of quotidian • hemodialysis on nutrition. Am J Kidney Dis 2003; 42:30–35.
34 The London, Ontatio study: nutrition.
35 Heidenheim AP, Murhead N, Moist L, Lindsay RM. Patient quality of life on quotidian hemodialysis. Am J Kidney Dis 2003; 42:36–41.
36 The London, Ontario study: quality of life.
37 Lockridge RS, Spencer M, Craft V, et al. Nightly home hemodialysis: Five and •• one-half years of experience in Lynchburg, Virginia. Hemodial Int 2004; 8:61–69.
38 The longest experience on nocturnal hemodialysis in the USA.
39 Kooistra MP, Vos J, Koomans HA, Vos PF. Daily home haemodialysis in The Netherlands: effects on metabolic control, haemodynamics, and quality of life. Nephrol Dial Transplant 1998; 13:2853–2860.
40 Pierratos A. Daily nocturnal home hemodialysis. Kidney Int 2004; 65: •• 1975–1986.
41 Review of the topic of daily nocturnal hemodialysis.
42 Mohr PE, Neumann PJ, Franco SJ, et al. The case for daily dialysis: its impact on costs and quality of life. Am J Kidney Dis 2001; 37:777–789.
43 Reynolds JT, Homel P, Cantey L, et al. A one-year trial of in-center daily hemodialysis with an emphasis on quality of life. Blood Purif 2004; 22: 320–328.
44 Quality of life on short daily hemodialysis.
45 McFarlane PA, Bayoumi AM, Pierratos A, Redelmeier DA. The quality of life •• and cost utility of home nocturnal and conventional in-center hemodialysis. Kidney Int 2003; 64:1004–1011.
46 Increased cost utility of nocturnal hemodialysis.
47 Guttiwiler JP, Schneditz D, Huber AR, et al. Estimating phosphate removal in hemodialysis: an additional tool to quantify dialysis dose. Nephrol Dial Transplant 2002; 17:1037–1044.
48 Gotch FA, Panilio F, Sergeyeva O, et al. A kinetic model of inorganic phosphorus mass balance in hemodialysis therapy. Blood Purif 2003; 21:51–57.
36 Galland R, Traeger J, Delawari E, Arkow PH. Optimal control of phosphatemia by short daily hemodialysis. Hemodial Int 2003; 7:73–74.
Effect of short daily hemodialysis on phosphate removal. Effect of increased protein intake.
37 Kim SJ, Goldstein M, Szabo T, Pierratos A. Resolution of massive uremic tumoral calcinosis with daily nocturnal home hemodialysis. Am J Kidney Dis 2003; 41:12.
38 Al Hejaili F, Kortas C, Leitch R, et al. Nocturnal but not short hours of nocturnal hemodialysis requires an elevated dialedlate calcium concentration. J Am Soc Nephrol 2003; 14:2392–2398.
39 Traeger J, Galland R, Delawari E, et al. Six years’ experience with short daily hemodialysis: Do the early improvements persist in the mid and long term? Hemodial Int 2004; 8:151–158.
Long-term effect of short daily hemodialysis on nutrition.
40 Agar JWM, Somerville CA, Dwyer KM, et al. Nocturnal hemodialysis in Australia. Hemodial Int 2003; 7:278–289.
41 Geary DF, Piva E, Gajaria M, et al. Development of a nocturnal home hemodialysis (NHHD) program for children. Semin Dial 2004; 17:115–117.
42 Fischbach M, Terzic J, Laugel V, et al. Relationship between volume control and blood pressure is different on short daily hemodialysis compared to nocturnal hemodialysis.
43 Fagugi RM, Pastini P, Quintaliani G, et al. Association between extracellular water, left ventricular mass and hypertension in haemodialysis patients. Nephrol Dial Transplant 2003; 18:2332–2338.
Decreased extracellular water correlates with blood pressure control and regression of cardiac mass.
44 Nesrallah G,帅R, Moist L, et al. Volume control and blood pressure management in patients undergoing intermittent home hemodialysis. Am J Kidney Dis 2003; 42:13–17.
45 Chan CT, Harvey PJ, Pictor P, et al. Short-term blood pressure, noradrenergic, and vascular effects of nocturnal home hemodialysis. Hypertension 2003; 42:925–931.
Nocturnal hemodialysis causes vasodilation and improves endothelial function.
46 Chan CT, Floras JS, Miller JA, et al. Regression of left ventricular hypertrophy after conversion to nocturnal hemodialysis. Kidney Int 2002; 61:2235–2239.
47 Chan C, Floras JS, Miller JA, Pierratos A. Improvement in ejection fraction by nocturnal haemodialysis in end-stage renal failure patients with coexisting heart failure. Nephrol Dial Transplant 2002; 17:1518–1521.
48 Chan CT, Harley P, Saurer J, et al. Impact of nocturnal hemodialysis on the variability of heart rate and duration of hypoxemia during sleep. Kidney Int 2004; 65:681–685.
Nocturnal hemodialysis increases heart rate variability (predictor of cardiac arrhythmias) during sleep.
49 Harly PJ, Pierratos A. Improvement of sleep apnea in patients with chronic renal failure who undergo nocturnal hemodialysis. N Engl J Med 2001; 344:102–107.
50 Chan CT, Mardrossian S, Farara R, Richardson RM. Improvement in lower-extremity peripheral arterial disease by nocturnal hemodialysis. Am J Kidney Dis 2003; 41:225–229.
51 Bugeja AL, Chan CT, Improvement in lipid profile by nocturnal hemodialysis in patients with end-stage renal disease. ASAIO J 2004; 50:328–331.
52 McCormick BB, Pierratos A, Fenton S, et al. Review of clinical outcomes in nocturnal haemodialysis patients after renal transplantation. Nephrol Dial Transplant 2004; 19:714–719.
53 Chan CT, Harvey PJ, Pierratos A, et al. Importance of phosphate control for restoration of vascular responsiveness in end-stage renal disease patients converted to nocturnal hemodialysis. Hemodial Int 2004; 8:91.
Serum phosphate on conventional hemodialysis correlates with the speed of recovery of endothelial function after conversion to nocturnal quotidian hemodialysis.